Genentech’s crovalimab meets co-primary efficacy endpoints in phase 3 PNH study
Results of the late-stage study demonstrated that crovalimab administered as a subcutaneous injection every four weeks, controlled the…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Feb 23
Results of the late-stage study demonstrated that crovalimab administered as a subcutaneous injection every four weeks, controlled the…
06 Feb 23
The approval is backed by efficacy data from the phase 3 HELP study with additional data from the…
03 Feb 23
The company anticipates investing nearly €40m in the new plasmid DNA manufacturing facility
01 Feb 23
Amjevita will be offered in a citrate-free formulation to reduce pain at the injection site and will be…
30 Jan 23
Lecanemab is an Aβ protofibril antibody, which is approved in the US for the treatment of Alzheimer’s disease…
27 Jan 23
The TRANSCEND CLL 004 trial evaluated the CAR T cell therapy in patients with relapsed or refractory chronic…
24 Jan 23
The addition of Mycamine is expected to considerably strengthen Sandoz’s hospital offering, anti-infective portfolio, and a global programme…
23 Jan 23
South Korea's MFDS determined that GX-188E met the requirements for fast track status after reviewing data from a…
20 Jan 23
Concert Pharmaceuticals’ deuruxolitinib is an oral inhibitor of Janus kinases JAK1 and JAK2, which is currently in late-stage…
17 Jan 23
BAT1806 has been indicated for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome